Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Borja Ibáñez MD, PhD

Borja Ibáñez MD, PhD

Director, Clinical Research Department, Spanish National Center for Cardiovascular Research (CNIC); Cardiology Department, Fundación Jiménez Díaz University Hospital; Group Leader, CIBERCV, Madrid, Spain

Borja Ibáñez is a clinician/scientist who combines research activites as scientific director of the Spanish National Center for Cardiovascular Research (CNIC, and as member of the CIBERCV, with clinical activities as interventional cardiologist at University Hospital Fundación Jiménez Díaz. He received training in Madrid and in Mount Sinai Heart, New York NY. His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure and cardiooncology. He actively participates in primary prevention studies focused on atherosclerosis early identification by imaging to improve risk prediction. He is PI of several multicenter clinical trials recruiting patients with myocardial infarction and heart failure, including the megatrial REBOOT, enrolling 8500 post-MI with normal ejection fraction randomized to beta-blockers or not.

He has published more than 350 scientific publications, with an H-index of 74 (scholar). He has received numerous awards for his scientific merits, including the Banco de Sabadell, Constantes y Vitales, Princesa de Girona, and Fundación Jesús Serra among others.

He served as the Chairman of the 2017 ESC STEMI Guidelines and is the Chairman of the forthcoming 2023 ESC Guidelines for the management of ACS.


Dr. Ibáñez has no relevant disclosures.